CTLA4 and neoplasm: Anti-PD1 treatment seems to increase the risk for pneumonitis, hypothyroidism, myalgia and arthralgia, whereas for anti-CTLA-4 colitis and hypophysitis were more frequently described, and variations have been seen observed depending on the underlying tumor type [71,72].